APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sustained Release Ocular Drug Delivery Systems

Compare research editions
View pricing & licenses

Selected research

Industry Research

Sustained Release Ocular Drug Delivery Systems Industry Research Report 2026

26 December 2025121 pages

Choose your research edition.

Industry ResearchSustained Release Ocular Drug Delivery Systems Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Sustained Release Ocular Drug Delivery Systems Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Sustained Release Ocular Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sustained Release Ocular Drug Delivery Systems Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Sustained Release Ocular Drug Delivery Systems Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Sustained Release Ocular Drug Delivery Systems market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Sustained Release Ocular Drug Delivery Systems is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Sustained Release Ocular Drug Delivery Systems is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Sustained Release Ocular Drug Delivery Systems is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Sustained Release Ocular Drug Delivery Systems include Aciont Inc., Allergan, Envisia Therapeutics, GrayBug, Icon Bioscience, Innocore Pharmaceuticals, Neurotech Pharmaceuticals, Ocular Therapeutix and OHR Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Sustained Release Ocular Drug Delivery Systems market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Sustained Release Ocular Drug Delivery Systems Market by Company

Aciont Inc.

Allergan

Envisia Therapeutics

GrayBug

Icon Bioscience

Innocore Pharmaceuticals

Neurotech Pharmaceuticals

Ocular Therapeutix

OHR Pharmaceuticals

PolyActiva

pSivida

TheraKine

Santen Pharmaceutical

Sustained Release Ocular Drug Delivery Systems Segment by Type

Microcapsules/Nanocapsules

Microspheres/Nanosptheres

Liposome

Implants

Sustained Release Ocular Drug Delivery Systems Segment by Application

Glaucoma

Corneal Transplantation

Cataract

Others

Sustained Release Ocular Drug Delivery Systems Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Ocular Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Ocular Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Ocular Drug Delivery Systems.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Sustained Release Ocular Drug Delivery Systems manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Sustained Release Ocular Drug Delivery Systems by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Sustained Release Ocular Drug Delivery Systems in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Sustained Release Ocular Drug Delivery Systems Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Sustained Release Ocular Drug Delivery Systems Sales (W Units) of Manufacturers (2021-2026) Table 7. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Manufacturers (2021-2026) Table 8. Global Sustained Release Ocular Drug Delivery Systems Revenue of Manufacturers (2021-2026) Table 9. Global Sustained Release Ocular Drug Delivery Systems Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Sustained Release Ocular Drug Delivery Systems Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Sustained Release Ocular Drug Delivery Systems Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Product Type & Application Table 14. Global Sustained Release Ocular Drug Delivery Systems Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Sustained Release Ocular Drug Delivery Systems by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Aciont Inc. Company Information Table 19. Aciont Inc. Business Overview Table 20. Aciont Inc. Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Aciont Inc. Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 22. Aciont Inc. Recent Developments Table 23. Allergan Company Information Table 24. Allergan Business Overview Table 25. Allergan Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Allergan Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 27. Allergan Recent Developments Table 28. Envisia Therapeutics Company Information Table 29. Envisia Therapeutics Business Overview Table 30. Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 32. Envisia Therapeutics Recent Developments Table 33. GrayBug Company Information Table 34. GrayBug Business Overview Table 35. GrayBug Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. GrayBug Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 37. GrayBug Recent Developments Table 38. Icon Bioscience Company Information Table 39. Icon Bioscience Business Overview Table 40. Icon Bioscience Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Icon Bioscience Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 42. Icon Bioscience Recent Developments Table 43. Innocore Pharmaceuticals Company Information Table 44. Innocore Pharmaceuticals Business Overview Table 45. Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 47. Innocore Pharmaceuticals Recent Developments Table 48. Neurotech Pharmaceuticals Company Information Table 49. Neurotech Pharmaceuticals Business Overview Table 50. Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 52. Neurotech Pharmaceuticals Recent Developments Table 53. Ocular Therapeutix Company Information Table 54. Ocular Therapeutix Business Overview Table 55. Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 57. Ocular Therapeutix Recent Developments Table 58. OHR Pharmaceuticals Company Information Table 59. OHR Pharmaceuticals Business Overview Table 60. OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 62. OHR Pharmaceuticals Recent Developments Table 63. PolyActiva Company Information Table 64. PolyActiva Business Overview Table 65. PolyActiva Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. PolyActiva Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 67. PolyActiva Recent Developments Table 68. pSivida Company Information Table 69. pSivida Business Overview Table 70. pSivida Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. pSivida Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 72. pSivida Recent Developments Table 73. TheraKine Company Information Table 74. TheraKine Business Overview Table 75. TheraKine Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. TheraKine Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 77. TheraKine Recent Developments Table 78. Santen Pharmaceutical Company Information Table 79. Santen Pharmaceutical Business Overview Table 80. Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 82. Santen Pharmaceutical Recent Developments Table 83. Global Sustained Release Ocular Drug Delivery Systems Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2021-2026) & (W Units) Table 85. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Region (2021-2026) Table 86. Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2027-2032) & (W Units) Table 87. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Region (2027-2032) Table 88. Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region (2021-2026) Table 90. Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region (2027-2032) Table 92. North America Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 94. North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 95. North America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 99. Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 100. Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 104. Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 105. Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 109. South America Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 110. South America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 114. Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 115. Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2026) & (W Units) Table 118. Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2027-2032) & (W Units) Table 119. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2026) Table 120. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2027-2032) Table 121. Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2026) Table 124. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2027-2032) Table 125. Global Sustained Release Ocular Drug Delivery Systems Price by Type (2021-2026) & (US$/Unit) Table 126. Global Sustained Release Ocular Drug Delivery Systems Price by Type (2027-2032) & (US$/Unit) Table 127. Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2026) & (W Units) Table 128. Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2027-2032) & (W Units) Table 129. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2026) Table 130. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2027-2032) Table 131. Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2026) Table 134. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2027-2032) Table 135. Global Sustained Release Ocular Drug Delivery Systems Price by Application (2021-2026) & (US$/Unit) Table 136. Global Sustained Release Ocular Drug Delivery Systems Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Sustained Release Ocular Drug Delivery Systems Distributors List Table 140. Sustained Release Ocular Drug Delivery Systems Customers List Table 141. Sustained Release Ocular Drug Delivery Systems Industry Trends Table 142. Sustained Release Ocular Drug Delivery Systems Industry Drivers Table 143. Sustained Release Ocular Drug Delivery Systems Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Sustained Release Ocular Drug Delivery Systems Product Image Figure 5. Global Sustained Release Ocular Drug Delivery Systems Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Sustained Release Ocular Drug Delivery Systems Market Size (2021-2032) & (US$ Million) Figure 7. Global Sustained Release Ocular Drug Delivery Systems Sales (2021-2032) & (W Units) Figure 8. Global Sustained Release Ocular Drug Delivery Systems Average Price (US$/Unit) & (2021-2032) Figure 9. Microcapsules/Nanocapsules Product Image Figure 10. Microspheres/Nanosptheres Product Image Figure 11. Liposome Product Image Figure 12. Implants Product Image Figure 13. Glaucoma Product Image Figure 14. Corneal Transplantation Product Image Figure 15. Cataract Product Image Figure 16. Others Product Image Figure 17. Global Sustained Release Ocular Drug Delivery Systems Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Sustained Release Ocular Drug Delivery Systems Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Sustained Release Ocular Drug Delivery Systems Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Sustained Release Ocular Drug Delivery Systems Sales by Region in 2025 Figure 23. Global Sustained Release Ocular Drug Delivery Systems Revenue by Region in 2025 Figure 24. North America Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025 Figure 25. North America Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 26. North America Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032) Figure 27. United States Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025 Figure 31. Europe Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 32. Europe Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032) Figure 33. Germany Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025 Figure 44. Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032) Figure 46. China Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025 Figure 55. South America Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 56. South America Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032) Figure 57. Brazil Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025 Figure 62. Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032) Figure 64. Egypt Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2032) Figure 70. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2032) Figure 71. Global Sustained Release Ocular Drug Delivery Systems Price (US$/Unit) by Type (2021-2032) Figure 72. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2032) Figure 73. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2032) Figure 74. Global Sustained Release Ocular Drug Delivery Systems Price (US$/Unit) by Application (2021-2032) Figure 75. Sustained Release Ocular Drug Delivery Systems Value Chain Figure 76. Sustained Release Ocular Drug Delivery Systems Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Sustained Release Ocular Drug Delivery Systems Industry Opportunities and Challenges

Scope & coverage.

Types
  • Microcapsules/Nanocapsules
  • Microspheres/Nanosptheres
  • Liposome
  • Implants
Applications
  • Glaucoma
  • Corneal Transplantation
  • Cataract
  • Others
Companies covered
  • Aciont Inc.
  • Allergan
  • Envisia Therapeutics
  • GrayBug
  • Icon Bioscience
  • Innocore Pharmaceuticals
  • Neurotech Pharmaceuticals
  • Ocular Therapeutix
  • OHR Pharmaceuticals
  • PolyActiva
  • pSivida
  • TheraKine
  • Santen Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Sustained Release Ocular Drug Delivery Systems Market Size (2021-2032)
  4. 2.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales (2021-2032)
  5. 2.2.3 Global Sustained Release Ocular Drug Delivery Systems Market Average Price (2021-2032)
  6. 2.3 Sustained Release Ocular Drug Delivery Systems by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Microcapsules/Nanocapsules
  9. 2.3.3 Microspheres/Nanosptheres
  10. 2.3.4 Liposome
  11. 2.3.5 Implants
  12. 2.4 Sustained Release Ocular Drug Delivery Systems by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Glaucoma
  15. 2.4.3 Corneal Transplantation
  16. 2.4.4 Cataract
  17. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Sustained Release Ocular Drug Delivery Systems Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Sustained Release Ocular Drug Delivery Systems Sales (W Units) of Manufacturers (2021-2026)
  3. 3.3 Global Sustained Release Ocular Drug Delivery Systems Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Sustained Release Ocular Drug Delivery Systems Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Sustained Release Ocular Drug Delivery Systems Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Product Type & Application
  8. 3.8 Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Established Date
  9. 3.9 Global Sustained Release Ocular Drug Delivery Systems Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Aciont Inc.
  2. 4.1.1 Aciont Inc. Company Information
  3. 4.1.2 Aciont Inc. Business Overview
  4. 4.1.3 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Product Portfolio
  6. 4.1.5 Aciont Inc. Recent Developments
  7. 4.2 Allergan
  8. 4.2.1 Allergan Company Information
  9. 4.2.2 Allergan Business Overview
  10. 4.2.3 Allergan Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Allergan Sustained Release Ocular Drug Delivery Systems Product Portfolio
  12. 4.2.5 Allergan Recent Developments
  13. 4.3 Envisia Therapeutics
  14. 4.3.1 Envisia Therapeutics Company Information
  15. 4.3.2 Envisia Therapeutics Business Overview
  16. 4.3.3 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Product Portfolio
  18. 4.3.5 Envisia Therapeutics Recent Developments
  19. 4.4 GrayBug
  20. 4.4.1 GrayBug Company Information
  21. 4.4.2 GrayBug Business Overview
  22. 4.4.3 GrayBug Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 GrayBug Sustained Release Ocular Drug Delivery Systems Product Portfolio
  24. 4.4.5 GrayBug Recent Developments
  25. 4.5 Icon Bioscience
  26. 4.5.1 Icon Bioscience Company Information
  27. 4.5.2 Icon Bioscience Business Overview
  28. 4.5.3 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Product Portfolio
  30. 4.5.5 Icon Bioscience Recent Developments
  31. 4.6 Innocore Pharmaceuticals
  32. 4.6.1 Innocore Pharmaceuticals Company Information
  33. 4.6.2 Innocore Pharmaceuticals Business Overview
  34. 4.6.3 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
  36. 4.6.5 Innocore Pharmaceuticals Recent Developments
  37. 4.7 Neurotech Pharmaceuticals
  38. 4.7.1 Neurotech Pharmaceuticals Company Information
  39. 4.7.2 Neurotech Pharmaceuticals Business Overview
  40. 4.7.3 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
  42. 4.7.5 Neurotech Pharmaceuticals Recent Developments
  43. 4.8 Ocular Therapeutix
  44. 4.8.1 Ocular Therapeutix Company Information
  45. 4.8.2 Ocular Therapeutix Business Overview
  46. 4.8.3 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Product Portfolio
  48. 4.8.5 Ocular Therapeutix Recent Developments
  49. 4.9 OHR Pharmaceuticals
  50. 4.9.1 OHR Pharmaceuticals Company Information
  51. 4.9.2 OHR Pharmaceuticals Business Overview
  52. 4.9.3 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
  54. 4.9.5 OHR Pharmaceuticals Recent Developments
  55. 4.10 PolyActiva
  56. 4.10.1 PolyActiva Company Information
  57. 4.10.2 PolyActiva Business Overview
  58. 4.10.3 PolyActiva Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 PolyActiva Sustained Release Ocular Drug Delivery Systems Product Portfolio
  60. 4.10.5 PolyActiva Recent Developments
  61. 4.11 pSivida
  62. 4.11.1 pSivida Company Information
  63. 4.11.2 pSivida Business Overview
  64. 4.11.3 pSivida Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 pSivida Sustained Release Ocular Drug Delivery Systems Product Portfolio
  66. 4.11.5 pSivida Recent Developments
  67. 4.12 TheraKine
  68. 4.12.1 TheraKine Company Information
  69. 4.12.2 TheraKine Business Overview
  70. 4.12.3 TheraKine Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 TheraKine Sustained Release Ocular Drug Delivery Systems Product Portfolio
  72. 4.12.5 TheraKine Recent Developments
  73. 4.13 Santen Pharmaceutical
  74. 4.13.1 Santen Pharmaceutical Company Information
  75. 4.13.2 Santen Pharmaceutical Business Overview
  76. 4.13.3 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Product Portfolio
  78. 4.13.5 Santen Pharmaceutical Recent Developments
5 Global Sustained Release Ocular Drug Delivery Systems Market Scenario by Region
  1. 5.1 Global Sustained Release Ocular Drug Delivery Systems Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2021-2032
  3. 5.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2021-2026
  4. 5.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2027-2032
  5. 5.3 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region: 2021-2032
  6. 5.3.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region: 2021-2026
  7. 5.3.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region: 2027-2032
  8. 5.4 North America Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
  9. 5.4.1 North America Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  11. 5.4.3 North America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
  16. 5.5.1 Europe Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  18. 5.5.3 Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
  41. 5.7.1 South America Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  43. 5.7.3 South America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2032)
  2. 6.1.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2032) & (W Units)
  3. 6.1.2 Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2032)
  4. 6.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2021-2032)
  5. 6.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Sustained Release Ocular Drug Delivery Systems Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2032)
  2. 7.1.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2032) & (W Units)
  3. 7.1.2 Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2032)
  4. 7.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2021-2032)
  5. 7.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Sustained Release Ocular Drug Delivery Systems Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Sustained Release Ocular Drug Delivery Systems Value Chain Analysis
  2. 8.1.1 Sustained Release Ocular Drug Delivery Systems Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Sustained Release Ocular Drug Delivery Systems Production Mode & Process
  5. 8.2 Sustained Release Ocular Drug Delivery Systems Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Sustained Release Ocular Drug Delivery Systems Distributors
  8. 8.2.3 Sustained Release Ocular Drug Delivery Systems Customers
9 Global Sustained Release Ocular Drug Delivery Systems Analyzing Market Dynamics
  1. 9.1 Sustained Release Ocular Drug Delivery Systems Industry Trends
  2. 9.2 Sustained Release Ocular Drug Delivery Systems Industry Drivers
  3. 9.3 Sustained Release Ocular Drug Delivery Systems Industry Opportunities and Challenges
  4. 9.4 Sustained Release Ocular Drug Delivery Systems Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst